Literature DB >> 8078499

Binding of [26-3H]bryostatin 1 and analogs to calcium-dependent and calcium-independent protein kinase C isozymes.

M G Kazanietz1, N E Lewin, F Gao, G R Pettit, P M Blumberg.   

Abstract

In this study we explored the pattern of protein kinase C (PKC) isozyme selectivity of the bryostatins, a unique class of PKC activators that induce only a subset of the typical phorbol ester responses and antagonize those phorbol ester-mediated responses that they themselves fail to induce. The binding properties of individual recombinant PKC isozymes that had been expressed in insect cells, isolated, and reconstituted in Triton X-100/phosphatidylserine mixed micelles were determined. [3H]Bryostatin 1 showed lower affinity for PKC-beta 1 and -gamma, compared with PKC-alpha, -delta, -epsilon, and -eta. This pattern contrasts with that observed for other PKC ligands. These latter assays were conducted with isozymes reconstituted in phosphatidylserine, conditions that unfortunately do not permit quantitation of bryostatin 1 binding under equilibrium conditions. Using delta 19,20-bryostatin 10 and delta 19,20-isobryostatin 10, we could distinguish the respective roles of ligand and lipid in the pattern of selectivity. When isozymes were reconstituted in phosphatidylserine vesicles, delta 19,20-bryostatin 10 and delta 19,20-isobryostatin 10 showed similar affinities for PKC-alpha and -gamma, similarly to the phorbol esters. However, in the mixed micellar system, PKC-gamma showed a significantly lower binding affinity, as had been observed for bryostatin 1. These results suggest that the unique pattern of biological responses to the bryostatins does not represent a unique pattern of isotype recognition. Furthermore, the lipid environment of PKC plays an important role in determining the binding selectivity for individual isozymes.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8078499

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  18 in total

1.  Activated NKT cells and NK cells render T cells resistant to myeloid-derived suppressor cells and result in an effective adoptive cellular therapy against breast cancer in the FVBN202 transgenic mouse.

Authors:  Maciej Kmieciak; Debasmita Basu; Kyle K Payne; Amir Toor; Adly Yacoub; Xiang-Yang Wang; Lisa Smith; Harry D Bear; Masoud H Manjili
Journal:  J Immunol       Date:  2011-06-13       Impact factor: 5.422

Review 2.  Protein kinase C and cancer: what we know and what we do not.

Authors:  R Garg; L G Benedetti; M B Abera; H Wang; M Abba; M G Kazanietz
Journal:  Oncogene       Date:  2013-12-16       Impact factor: 9.867

Review 3.  Protein kinase C in cancer: The top five unanswered questions.

Authors:  Mariana Cooke; Andrew Magimaidas; Victoria Casado-Medrano; Marcelo G Kazanietz
Journal:  Mol Carcinog       Date:  2017-03-10       Impact factor: 4.784

4.  Bryostatin 1 inhibits phorbol ester-induced apoptosis in prostate cancer cells by differentially modulating protein kinase C (PKC) delta translocation and preventing PKCdelta-mediated release of tumor necrosis factor-alpha.

Authors:  Vivian A von Burstin; Liqing Xiao; Marcelo G Kazanietz
Journal:  Mol Pharmacol       Date:  2010-06-01       Impact factor: 4.436

5.  Phenotype, functions and fate of adoptively transferred tumor draining lymphocytes activated ex vivo in mice with an aggressive weakly immunogenic mammary carcinoma.

Authors:  Catriona H T Miller; Laura Graham; Harry D Bear
Journal:  BMC Immunol       Date:  2010-11-04       Impact factor: 3.615

6.  Peripheral blood mononuclear cells of patients with breast cancer can be reprogrammed to enhance anti-HER-2/neu reactivity and overcome myeloid-derived suppressor cells.

Authors:  Kyle K Payne; Christine K Zoon; Wen Wan; Khin Marlar; Rebecca C Keim; Mehrab Nasiri Kenari; A Latif Kazim; Harry D Bear; Masoud H Manjili
Journal:  Breast Cancer Res Treat       Date:  2013-10-25       Impact factor: 4.872

7.  Evaluation of Chromane-Based Bryostatin Analogues Prepared via Hydrogen-Mediated C-C Bond Formation: Potency Does Not Confer Bryostatin-like Biology.

Authors:  John M Ketcham; Ivan Volchkov; Te-Yu Chen; Peter M Blumberg; Noemi Kedei; Nancy E Lewin; Michael J Krische
Journal:  J Am Chem Soc       Date:  2016-09-27       Impact factor: 15.419

8.  IL-7 + IL-15 are superior to IL-2 for the ex vivo expansion of 4T1 mammary carcinoma-specific T cells with greater efficacy against tumors in vivo.

Authors:  Esther Cha; Laura Graham; Masoud H Manjili; Harry D Bear
Journal:  Breast Cancer Res Treat       Date:  2009-10-14       Impact factor: 4.872

9.  Biological profile of the less lipophilic and synthetically more accessible bryostatin 7 closely resembles that of bryostatin 1.

Authors:  Noemi Kedei; Nancy E Lewin; Tamás Géczy; Julia Selezneva; Derek C Braun; Jinqiu Chen; Michelle A Herrmann; Madeleine R Heldman; Langston Lim; Poonam Mannan; Susan H Garfield; Yam B Poudel; Thomas J Cummins; Arnab Rudra; Peter M Blumberg; Gary E Keck
Journal:  ACS Chem Biol       Date:  2013-02-01       Impact factor: 5.100

10.  Incubation of antigen-sensitized T lymphocytes activated with bryostatin 1 + ionomycin in IL-7 + IL-15 increases yield of cells capable of inducing regression of melanoma metastases compared to culture in IL-2.

Authors:  Hanh K Le; Laura Graham; Catriona H T Miller; Maciej Kmieciak; Masoud H Manjili; Harry Douglas Bear
Journal:  Cancer Immunol Immunother       Date:  2009-02-06       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.